---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-040679"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2024-10-10T23:59:59+00:00"
generated_at: "2026-05-30T16:42:58.721481+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# bioAffinity appoints J. Michael Edwards as CFO; $300k salary, $50k bonus, 100k RSUs

## Summary
- J. Michael Edwards appointed CFO effective Nov 5, 2024; annual base salary of $300,000.
- Signing bonus: $50,000 cash and restricted stock award of 100,000 shares vesting 25% immediately, then over 3 years.
- Edwards previously served as CFO from 2014-2023, oversaw 2022 IPO, and has been interim CFO since Sept 2024.
- Employment agreement has one-year initial term, auto-renews annually; he reports to CEO Maria Zannes.
- Company highlights Edwards' experience for commercialization of CyPath Lung, a noninvasive lung cancer test.

## SEC filing metadata
- accession: 0001493152-24-040679
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2024-10-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315224040679/0001493152-24-040679-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315224040679/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-040679
- JSON: https://secwatch.observer/filing/0001493152-24-040679.json
- Plain text: https://secwatch.observer/filing/0001493152-24-040679.txt

## Key facts
- Executive change
  J. Michael Edwards was appointed as Chief Financial Officer at bioAffinity Technologies, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On October 4, 2024, the Board of Directors (the “Board”) of bioAffinity technologies, Inc. (the “Company”) appointed J. Michael Edwards, who has served as the Company’s Interim Chief Financial Officer, as a consultant, since September 2024, to serve as Chief Financial Officer of the Company, effective November 5, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1712762/000149315224040679/0001493152-24-040679-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.